Diclofenac sodium
Voltaren SR 100 and Voltaren are different trade names for the same medicine.
Voltaren SR 100 contains diclofenac sodium, which belongs to the group of non-steroidal anti-inflammatory drugs (NSAIDs), which have anti-rheumatic, anti-inflammatory, analgesic, and antipyretic effects. The mechanism of action of Voltaren SR 100 involves the inhibition of prostaglandin biosynthesis, which plays a fundamental role in the pathogenesis of inflammation, pain, and fever.
Voltaren SR 100 is used to treat:
In the case of diagnosed heart disease or significant risk factors for heart disease, the doctor will periodically assess the patient's need for symptomatic treatment and their response to the medicine, especially if treatment lasts longer than 4 weeks.
During treatment, regular blood tests should be performed in the event of any liver function disorders, kidney function disorders, and blood count disorders.
Both liver function (transaminase levels), kidney function (creatinine levels), and blood count (white blood cell count, red blood cell count, and platelet count) should be monitored. The doctor will take into account the results of blood tests when deciding to discontinue treatment with Voltaren SR 100 or change the dose of the medicine.
Like other non-steroidal anti-inflammatory drugs (NSAIDs), Voltaren SR 100 should not be taken by people who may experience an asthma attack, hives, or acute rhinitis after taking acetylsalicylic acid or other prostaglandin synthesis inhibitors.
The patient should inform their doctor about the above-mentioned diseases.
Before taking Voltaren SR 100, the patient should discuss the following with their doctor:
The medicine should be administered with caution (preferably under medical supervision);
Before taking diclofenac, the patient should inform their doctor
The medicine contains less than 1 mmol (23 mg) of sodium per tablet, which means it is considered "sodium-free".
Taking this type of medicine, such as Voltaren SR 100, may be associated with a small increased risk of heart attack (myocardial infarction) or stroke. This risk increases with long-term use of high doses of the medicine. The patient should not take higher doses or use the medicine for longer than recommended.
In the event of heart problems, a history of stroke, or suspected risk of these disorders (e.g. high blood pressure, diabetes, high cholesterol levels, smoking), the patient should discuss their treatment with their doctor or pharmacist.
The medicine may temporarily inhibit platelet aggregation.
The medicine is not recommended for children and adolescents due to the dose size.
Elderly patients may be more sensitive to the effects of the medicine than other adults. The patient should follow the recommendations in the leaflet, take the smallest effective dose as recommended by the doctor, and report any side effects that occur during treatment to their doctor.
The patient should tell their doctor about all medicines they are currently taking or have recently taken, as well as any medicines they plan to take.
The tablets should be swallowed whole, with a glass of water, preferably during a meal.
If the patient is pregnant or breastfeeding, thinks they may be pregnant, or plans to have a child, they should consult their doctor before taking this medicine.
During pregnancy, during the first two trimesters, if it is not absolutely necessary, Voltaren SR 100 should not be taken.
As with other anti-inflammatory drugs, taking Voltaren SR 100 in the last 3 months of pregnancy is contraindicated, as it may seriously harm the fetus or have an adverse effect on labor.
Voltaren SR 100 should not be taken by breastfeeding women, as it may have adverse effects on the infant.
The doctor will discuss the potential risks of taking Voltaren SR 100 during pregnancy and breastfeeding with the patient.
Taking Voltaren SR 100 may make it more difficult to become pregnant. If the patient plans to become pregnant or is having trouble becoming pregnant, they should inform their doctor.
The effect of Voltaren SR 100 on the ability to drive and use machines is unlikely.
Voltaren SR 100 in the form of prolonged-release tablets contains sucrose. If the patient has previously been diagnosed with intolerance to some sugars, they should consult their doctor before taking the medicine.
This medicine should always be taken as directed by the doctor. In case of doubts, the patient should consult their doctor or pharmacist.
Voltaren SR 75 (75 mg) and Voltaren SR 100 (100 mg) are available on the market.
The recommended dose should not be exceeded. If the patient is taking Voltaren SR 100 prolonged-release tablets for more than a few weeks, they should have regular medical check-ups to rule out any unnoticed side effects. The general recommendation is for the doctor to adjust the dose individually for each patient and use the smallest effective dose for the shortest possible period.
If the patient feels that the effect of the medicine is too strong or too weak, they should consult their doctor.
The recommended initial daily dose is 100 mg to 150 mg, given as one Voltaren SR 100 tablet or two Voltaren SR 75 tablets.
In milder cases and in chronic treatment, one Voltaren SR 75 or Voltaren SR 100 tablet per day is usually sufficient.
If the symptoms are most pronounced at night or in the morning, the patient should take Voltaren SR 75 or Voltaren SR 100 in the evening.
Due to the dose size, Voltaren SR 100 is not recommended for children and adolescents under 18 years of age.
The medicine should be used with caution in elderly patients. In elderly patients and those with low body weight, the smallest effective dose is recommended.
Patients with diagnosed cardiovascular disease or significant risk factors for cardiovascular events should be treated with diclofenac only after careful consideration and with doses not exceeding 100 mg per day if treatment lasts longer than 4 weeks.
Voltaren SR 100 is contraindicated in patients with kidney failure.
No special studies have been conducted in patients with kidney function disorders, so no specific dosage recommendations can be made. Caution is recommended when administering Voltaren SR 100 to patients with mild to moderate kidney function disorders.
Voltaren SR 100 is contraindicated in patients with liver failure.
No special studies have been conducted in patients with liver function disorders, so no specific dosage recommendations can be made. Caution is recommended when administering Voltaren SR 100 to patients with mild to moderate liver function disorders.
If the symptoms are most pronounced at night or in the morning, Voltaren SR 100 should be taken in the evening. The tablets should be swallowed whole, with a glass of water, preferably during a meal. The tablets should not be divided or chewed.
Voltaren SR 100 should always be taken as directed by the doctor.
If the patient is taking Voltaren SR 100 for a long time, they should regularly consult their doctor to ensure that no side effects have occurred.
In case of doubts about how long to take the medicine, the patient should consult their doctor or pharmacist.
Overdosing on Voltaren SR 100 does not cause characteristic symptoms, but the following may occur: vomiting, gastrointestinal bleeding, diarrhea, dizziness, tinnitus, or seizures. In the case of significant poisoning, acute kidney failure and liver damage may occur.
In the event of accidental ingestion of a larger amount of tablets than recommended, the patient should immediately consult a doctor, pharmacist, or go to the emergency department.
If a dose is missed, the patient should take it as soon as they remember.
However, if more than half of the time has passed between two doses, the missed dose should not be taken, and the next dose should be taken according to the previous dosing schedule. The patient should not take a double dose to make up for the missed dose.
Like all medicines, Voltaren SR 100 can cause side effects, although not everybody gets them.
The frequency of side effects is estimated as follows:
very common (≥1/10); common (≥1/100 to <1>rare (≥1/10 000 to <1>The following side effects include those reported with Voltaren SR 100, as well as those observed with other forms of diclofenac, used for short or long periods.
Taking medicines like Voltaren SR 100 may be associated with a small increased risk of heart attack (myocardial infarction) or stroke.
In some people, while taking Voltaren SR 100, other side effects may occur. If any of the side effects worsen or if any side effects not listed in this leaflet occur, the patient should tell their doctor or pharmacist.
These uncommon side effects may occur in 1-10 patients out of 1000, especially when taking high daily doses (150 mg) for a long time
If the patient is taking Voltaren SR 100 for more than a few weeks, they should regularly consult their doctor to ensure that no side effects have occurred.
If side effects occur, including any side effects not listed in this leaflet, the patient should tell their doctor or pharmacist. Side effects can be reported directly to the Department of Adverse Reaction Monitoring of Medicinal Products, Medical Devices, and Biocidal Products, Al. Jerozolimskie 181C, 02-222 Warsaw, tel.: +48 22 49 21 301, fax: +48 22 49 21 309, website: https://smz.ezdrowie.gov.pl
Reporting side effects will help gather more information on the safety of the medicine.
The medicine should be stored out of sight and reach of children.
Store in a temperature below 30°C.
Do not use this medicine after the expiry date stated on the packaging. The expiry date refers to the last day of the month.
Medicines should not be disposed of via wastewater or household waste. The patient should ask their pharmacist how to dispose of medicines that are no longer needed. This will help protect the environment.
One pack of Voltaren SR 100 contains 2 blisters of 10 prolonged-release tablets.
For more detailed information, the patient should contact the marketing authorization holder or parallel importer.
Novartis (Hellas) Α.Ε.Β.Ε.
12 km Ethniki Oldos Athinon-Lamias
144 51 Metamorfosi
Greece
Novartis Farma SpA, Torre Annunziata, Italy
Novartis (Hellas) A.E.B.E., Metamorfosi, Greece
InPharm Sp. z o.o.
ul. Strumykowa 28/11
03-138 Warsaw
InPharm Sp. z o.o. Services sp. k.
ul. Chełmżyńska 249
04-458 Warsaw
Marketing authorization number in Greece, the country of export:26179/24-04-2013
8546/6-2-2007
[Information about the trademark]
Need help understanding this medicine or your symptoms? Online doctors can answer your questions and offer guidance.